Keapstone Therapeutics

Keapstone Therapeutics is a private, preclinical-stage biotech founded in 2021, originating from the Sheffield Institute for Translational Neuroscience. The company is pioneering a unique approach to neuroprotection by developing small molecules that activate the Nrf2 pathway, aiming to simultaneously improve redox balance, mitochondrial function, autophagy, and reduce inflammation. With strong academic roots and backing from Parkinson's UK, Keapstone is advancing its platform towards treatments for neurodegenerative diseases with high unmet need, though it faces significant development and competitive risks inherent to CNS drug discovery.

Development of CNS-penetrant, non-reactive small molecules that block the KEAP1-Nrf2 protein-protein interaction, leading to activation of the Nrf2-ARE pathway and upregulation of multiple cellular defense mechanisms.

The competitive landscape includes other companies targeting the Nrf2 pathway (e.g., with electrophilic activators or other mechanisms) and a broad array of biopharma firms pursuing diverse neuroprotective approaches for Parkinson's and ALS. Keapstone aims to differentiate itself with its specific focus on non-reactive, CNS-penetrant KEAP1-Nrf2 interaction inhibitors.